Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | P2RY1 | P47900 | 4/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 3/20 | 1.00 |
| ▸ | P2RX5 | Q93086 | 2/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.86 |
| ▸ | HPGD | P15428 | 2/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.86 |
| ▸ | P2RY13 | Q9BPV8 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236767 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL29357199 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL5287746 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL7196930 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL7196945 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| Isoppads SCHEMBL29494952 | 0.93 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| Isoppads SCHEMBL14702227 | 0.93 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL16450980 | 0.89 | MAPT (0.79) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL29374112 | 0.88 | MAPT (0.78) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL15354624 | 0.86 | MAPT (0.76) | MAPTTDP1P2RY1P2RX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | claimed |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-30 | — | — | US | disclosed |
| US-9872875-B2 | Component and method for treating viral disease | HONZ PHARMACEUTICAL CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-9546139-B2 | Pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-01-17 | — | — | US | disclosed |
| US-9546139-B2 | Pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-01-17 | — | — | US | disclosed |
| US-20150045318-A1 | COMPONENT AND METHOD FOR TREATING VIRAL DISEASE | HONZ PHARMACEUTICAL CO., LTD. (CN) | 2015-02-12 | — | — | US | disclosed |
| US-20130040997-A1 | NOVEL PYRIDINE CARBOXYLIC ACID BASED COMPOUND USED AS A P2X1 AND P2X3 RECEPTOR ANTAGONIST, A PRODUCTION METHOD FOR THE SAME AND A COMPOSITION COMPRISING THE SAME | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040997-A1 | NOVEL PYRIDINE CARBOXYLIC ACID BASED COMPOUND USED AS A P2X1 AND P2X3 RECEPTOR ANTAGONIST, A PRODUCTION METHOD FOR THE SAME AND A COMPOSITION COMPRISING THE SAME | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-14 | — | — | US | disclosed |
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | MAPT 4512/4885TDP1 504/4885P2RY1 21/4885 |
| US-20130040997-A1 | NOVEL PYRIDINE CARBOXYLIC ACID BASED COMPOUND USED AS A P2X1 AND P2X3 RECEPTOR ANTAGONIST, A PRODUCTION METHOD FOR THE SAME AND A COMPOSITION COMPRISING THE SAME | P2RX3, P2RX1, P2RX2 | MAPT 2226/4885TDP1 3900/4885P2RY1 8/4885 |
| US-20150045318-A1 | COMPONENT AND METHOD FOR TREATING VIRAL DISEASE | P2RX7, P2RX3, P2RX1 | MAPT 3504/4885TDP1 2729/4885P2RY1 10/4885 |
| US-20190160029-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | MAPT 4064/4885TDP1 2465/4885P2RY1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.